Kelly A. Demerino
Corporate Officer/Principal chez NUVO PHARMACEUTICALS INC.
Postes actifs de Kelly A. Demerino
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| NUVO PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/01/2021 | - |
| Comptroller/Controller/Auditor | 01/01/2019 | 01/01/2020 | |
| Directeur Financier/CFO | 01/01/2020 | 01/01/2021 |
Historique de carrière de Kelly A. Demerino
Formation de Kelly A. Demerino
| Mount Allison University | Undergraduate Degree |
Statistiques
Internationale
| Canada | 3 |
Opérationnelle
| Comptroller/Controller/Auditor | 1 |
| Director of Finance/CFO | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Nuvo Pharmaceuticals, Inc.
 Nuvo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada. | Health Technology |
- Bourse
- Insiders
- Kelly A. Demerino
- Expérience